source
- Licensing deals with Chinese biotech stay strong as big pharma pours $550M+ into cancer and obesity pipelinesWestern drug developers continue to sign licensing agreements with Chinese biotechnology firms at a steady pace, according to recent data visualizations. More than 100 such deals have been announc…
- Industry urges FDA to broaden prior-knowledge guidance for gene and cell therapiesIndustry stakeholders have asked the U.S. Food and Drug Administration to expand the scope of its recent draft guidance on scientifically valid prior knowledge for gene therapies that involve genom…